Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.

The FDA approved Johnson & Johnson’s Spravato nasal spray as a stand-alone treatment for patients suffering from severe ...

Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...

Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts.

The company said that the nasal spray is a ketamine-derived drug, first approved in 2019, to be used in combination with ...

The Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression. Here's what ...

The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...